Moreover, a multivariate analysis revealed that CD69 expression was the only factor that predicts response to bendamustine independently from other biological and clinical CLL features, pointing out a functional role of this protein in the mechanisms of resistance to bendamustine. This evidence concerns the gene CD69 and B-cell chronic lymphocytic leukemia.